Navigation Links
Lyle Arnold, PhD and Michael Dunn Join Biocept Management Team
Date:5/4/2011

SAN DIEGO, May 4, 2011 /PRNewswire/ -- Biocept, Inc. announced today that Lyle Arnold, PhD and Michael Dunn, MBA have joined Biocept's Management Team. Dr. Arnold will serve as Senior Vice President and Chief Scientific Officer (CSO) and Mr. Dunn will act as the Senior Vice President, Corporate Development.

"I am very excited about the addition of Lyle and Mike to the Biocept team," said Hale. "Each has significant experience and expertise in the diagnostic field and will provide invaluable insight regarding scientific and business opportunities for Biocept," continued Hale.

Lyle Arnold, PhD

Dr. Arnold is a biotechnology executive, entrepreneur, and developer of innovative technologies covering molecular diagnostics, genomics and therapeutics.  Dr. Arnold is a founder and director of Aegea Biotechnologies a next generation nucleic acid technology company.  Previously he was VP, Research at Gen-Probe from September 2003 to October 2009. He has also held senior scientific and management positions at Molecular Biosystems (co-founder), Genta, Synteni, Incyte Genomics, and Oasis Biosciences (co-founder).  In addition, Dr. Arnold was a faculty member in the UCSD School of Medicine and a member of the UCSD Cancer Center. Dr. Arnold is an inventor or co-inventor on 36 issued U.S. patents and more than 140 issued and pending patents worldwide. He is the principle inventor of the chemiluminescent Hybridization Protection Assay (HPA) and associated technologies, core to Gen-Probe assays that have generated more than $5B in product revenue. In addition, he has authored more than 50 scientific publications.  Dr. Arnold also serves on the board of directors of Asuragen, a rapidly emerging biotechnology company in Austin, Texas.   He received a B.S. in Chemistry from the University of California at Los Angeles and a Ph.D. in Chemistry/Biochemistry from the University of California at San Diego.

Mike Dunn, MBA

Mr. Dunn assumes the role of Senior Vice President, Corporate Development after serving as a consultant to Biocept for several months.  He has 30 years of experience in the diagnostics, pharmaceutical and biotech industries.  Prior to Biocept, Mr. Dunn served as Vice President and Chief Business Officer of Monogram Biosciences, a biotech laboratory specializing in infectious disease and cancer diagnostics, which was acquired by LabCorp in 2009.   Previously, Mr. Dunn served as Vice President and Chief Business Officer of ACLARA BioSciences, a company specializing in microfluidic chips and cancer diagnosis through its merger with Virologic, Inc., as well as Vice President and Chief Business Officer at ActivX Biosciences, a biopharmaceutical company that utilizes proteomics to discover and develop small molecule drugs for major unmet medical needs.  Additionally, Mr. Dunn served as Vice President of Business Development at Aurora Biosciences, a company that developed and commercialized proprietary drug discovery systems, services and technologies prior to its acquisition by Vertex Pharmaceutical in 2001.  Mr. Dunn began his biotech career with various project management and business development roles at the Salk Institute Biotechnology/Industrial Associates (SIBIA) and it's successor, SIBIA Neurosciences, culminating as VP of Business Development.  SIBIA was acquired by Merck in 1999.  Mr. Dunn holds a B.A. in Biology from the University of Chicago and a MBA in Finance from the University of San Diego. 

About Biocept, Inc.

Biocept Laboratories, headquartered in San Diego, California, is a diagnostic and advanced laboratory services company specializing in the capture, detection, isolation and molecular analysis of circulating tumor cells (CTCs). Biocept's mission is to enhance the lives of cancer patients through the development of innovative diagnostic products and services. Biocept utilizes patented and innovative technologies to deliver clinically relevant information to physicians that enable better patient care. This includes clinical assessments of CTCs, both prognostic and predictive, which may provide physicians with information highly relevant for the treatment of their patients with cancer.


'/>"/>
SOURCE Biocept, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... YORK , December 2, 2016 ... Braces & Support) is Expected to Gain a Significant Market ... to Orthopedic Ailments  ... , According to ... Study on Medical Implants Sterile Packaging: Clamshell Product Type Segment ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite and ... the Dow Jones Industrial Average managed to stay in green. ... which prompted Stock-callers this morning to look at the performances ... NUVA ), Smith & Nephew PLC (NYSE: SNN ... Cesca Therapeutics Inc. (NASDAQ: KOOL ). You can ...
(Date:12/2/2016)... -- The concept of rare diseases and the idea that ... has been taking shape in Europe ... initiatives related to orphan medicinal products have been emerging at ... states individually. Many member states in the EU have led ... medicinal products, the result of which took the shape of ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s ... ostomy patients, standing as living proof that attitude and determination can combine into ... issues that spike around the holidays. This campaign will offer patients a new-found ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet is proud to announce the ... the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and ... 6 years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... veterinarian diagnostic imaging systems and the first company to offer robotic ... a Heart at their tradeshow booth # 941 for the American Association of ...
(Date:12/2/2016)... Abilene, Texas (PRWEB) , ... December 02, 2016 , ... ... article that delves into how this current generation fits into Bible Prophecy. Yisrayl says ... lists various facts pointing to this conclusion, showing how the details line up exactly ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... meals to needy individuals and families from eight different sites throughout Miami-Dade and ... Day. Over 1,000 volunteers worked very hard on Thanksgiving morning by putting together ...
Breaking Medicine News(10 mins):